CONNECT WITH US:
Feb 11, 2020 16:30 JST
Novel approach from Synergy Pharmaceuticals may hold cure to herpes virus
Sydney, Aus, Feb 11, 2020 - (ACN Newswire) - There is an immediate need for alternative treatments to combat the spread of Herpes type 1 & 2 strains. The United States alone reports over 750,000 new cases of herpes infections every year. Alarming figures especially when coupled with the increased risk for pregnant women, newborn babies and with the incidence of herpes encephalitis on the rise. Existing options include antivirals that have been approved for clinical administration and a limited number of nucleoside analogues.
A recent study by Synergy Pharmaceuticals (www.synergy-pharmaceuticals.com) in association with ACU may set a new stream of thought on the topic by bringing back traditional medicine as an opportunity to make a difference. Their study served to investigate a relatively novel approach to breaking down the herpes viral envelope by employing specific T Cells generated through a particular Amino Acid formula.
The treatment consisted of five immunotherapeutic core compounds (5CC) comprising of Rhodiola, Tribulus, Astragalus, Lysine and a proprietary Amino Acid Formula. These 5CC are effective inhibitors of herpes viral DNA synthesis and interferon (IFN)-induced cellular antiviral response and were found to neutralize antiviral reproduction by blocking cell-to-cell infection.
The aim of this study was to explore alternative substitutes to treat herpes simplex virus infection and prevent viral reproduction where conventional medications had previously failed. Testing was performed using 5CC with immunotherapeutic features to be able to neutralize herpes viral activity inside the human body. For the first time, this study highlighted the combinations capacity to act by preventing cell-to-cell infection to suppress the activity of the virus.
The study also focused on the immune-inhibiting properties of the 5CC which indicated cell membrane breakdown and eradication. A randomized, investigator-blinded method was performed on patients with a moderate to high positive concentration of herpes serum antibodies. A longitudinal approach was adopted over 6 months, where participants' infection rates were measured at various points during the treatment. Antiviral activity of the 5CC against HSV-1 and HSV-2 was tested on RC-37 cells in vitro using a plaque reduction assay.
The study was able to validate that for some participants there was a noted progression from a positive antibody serology to a negative one. This was the first time evidence has documented a cure for the herpes simplex virus.
This research shows considerable scope, particularly in the natural approach to viral infection treatment options, while it is the first study that has documented herpes serum antibody results that confirmed a positive to negative transition for participants. The results validated the earlier aims that 5CC provides far greater elimination in viral cell breakdown than any other conventional antiviral medication or vaccine thus far. Indicators of the 5CC found that the combination exhibited high levels of virucidal activity against HSV-1 and HSV-2 in viral suspension. These results suggest that the 5CC are strong alternative candidates for treating herpes simplex.
Follow up investigations have demonstrated further promising results, still utilising the same 5CC from the study. In light of this research and the current demands for a more natural approach, Synergy has seen expansion across the Australian, American and Asian markets. Further avenues into Europe appear to be stagnant however due to limitations on the accessibility of imported natural medicine, a situation which may serve to highlight the drastic shortcomings in the over-regulation of health and supplements.
While this appears to be the first and only successful cure for the herpes virus the researchers went on to reflect; there is however, no immunity for sufferers once clear of the herpes virus, potentially leaving the door open to reinfection later if the individual is not careful. This study though may well pave the way for a departure from the standard antiviral pharmaceutical mentality, which has dominated medical profession culture on the treatment options for viral disease for so many years.
1. CDC. (January 31, 2017). Genital Herpes - CDC Fact Sheet (Detailed). Reference:
2. American Sexual Health Association. (April 18, 2019). Herpes treatment. Reference:
3. May, Brandon. (July 10, 2018). Abandoned Genital Herpes Vaccine GEN-003 Found to Reduce Lesions, Decrease Viral Shedding at Varying Doses. Reference:
4. Taylor, Marisa. (April 12, 2018). FDA Launches Criminal Investigation Into Unauthorized Herpes Vaccine Research. Reference:
5. Raymond, Nate. (December 7, 2018). Genocea Biosciences ducks investor lawsuit over herpes vaccine. Reference:
6. Sciforum Journals. (December 20, 2019). Isolation and elimination of Latent and Productive Herpes Simplex Virus from the Sacral and Trigeminal Ganglions. Reference:
7. Berman, Robby. (November 23, 2019). How dormant herpes springs back to life. Reference:
Source: Synergy Pharmaceuticals
Copyright ©2020 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Mitsubishi Power Expands Promotion of Proprietary Boiler Smart Inspection Service Package for Managing Power Generation Facilities
Sep 25, 2020 16:15 JST
Hitachi Begins Testing of 5G Powered Industrial IoT Solutions at its Silicon Valley Research Center in California, USA
Sep 25, 2020 15:44 JST
MITSUBISHI MOTORS Rolls Out the OUTLANDER PHEV in Puerto Rico
Sep 25, 2020 14:29 JST
NEC Face Recognition Engine Provides Highly Accurate Results Even When Face Masks are Worn
Sep 25, 2020 13:48 JST
Showa Denko Announces Merger between Consolidated Subsidiaries and Change of Company Name
Sep 24, 2020 19:00 JST
Fujitsu and SNP Announce Global Platinum Partnership Agreement -- Accelerating SAP S/4HANA Conversion Business with Advanced Data Transformation Technologies
Sep 24, 2020 14:55 JST
Hitachi ABB Power Grids to Invest Over $100 Million in Strategic Realignment of Global High-Voltage Switchgear Business
Sep 24, 2020 13:30 JST
Mitsubishi Corporation: Use of CO2 in Concrete / Partnership with Blue Planet Systems Corporation
Sep 23, 2020 16:00 JST
Hitachi Hosts "Hitachi Social Innovation Forum 2020 TOKYO ONLINE"
Sep 23, 2020 14:22 JST
Hitachi ABB Power Grids Launches Open and Scalable Ecosystem for Digitalization of Transformers
Sep 23, 2020 10:38 JST
Fujitsu to Deliver New Supercomputer System for Canon
Sep 23, 2020 10:25 JST
Eisai Receives Positive Opinion from EMA's CHMP on Use of Antiepileptic Agent Fycompa in Pediatric Patients
Sep 23, 2020 09:24 JST
Eisai and Merck Present First-Time Data From Two Studies Evaluating KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020
Sep 23, 2020 09:10 JST
Toyota Motor Corporation Announces Appointment of Tommi Makinen as a Motorsport Advisor
Sep 22, 2020 18:08 JST
Evans Claims Victory for TOYOTA GAZOO Racing on a Turbulent Final Day
Sep 21, 2020 10:48 JST
GR Super Sport Makes Dynamic Public Debut at Le Mans
Sep 21, 2020 10:24 JST
Toyota Gazoo Racing Takes Le Mans Hat-Trick
Sep 21, 2020 10:11 JST
MITSUBISHI MOTORS Redesigns New ECLIPSE CROSS, Also Offered with Plug-in Hybrid Powertrain
Sep 18, 2020 12:09 JST
Eisai Presents Latest Data of Phase I Clinical Trial on Liposomal Formulation of Anti-Cancer Agent Halaven (Eribulin) at ESMO Virtual Congress 2020
Sep 18, 2020 11:29 JST
Fujitsu Develops Technology to Block Facial Authentication Fraud
Sep 18, 2020 10:20 JST
More Latest Release >>